Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: A cross-sectional survey of the K13 molecular marker

The Lancet Infectious Diseases

Volumn 15, Issue 4, 2015, Pages 415-421

  Tun, Kyaw M ^a,b   Imwong, Mallika ^c   Lwin, Khin M ^c,d   Win, Aye A ^c,e   Hlaing, Tin M ^b   Hlaing, Thaung ^f   Lin, Khin ^g   Kyaw, Myat P ^g   Plewes, Katherine ^c,i   Faiz, M Abul ^c,j   Dhorda, Mehul ^h,i   Cheah, Phaik Yeong ^c,i   Pukrittayakamee, Sasithon ^c   Ashley, Elizabeth A ^c,i   Anderson, Tim J C ^k   Nair, Shalini ^k   McDew White, Marina ^k   Flegg, Jennifer A ^h,l   Grist, Eric P M ^h   Guerin, Philippe ^h   Maude, Richard J ^c,i   Smithuis, Frank ^a,i,m   Dondorp, Arjen M ^c,i   Day, Nicholas P J ^c,i   Nosten, François ^c,d,i   White, Nicholas J ^c,i   Woodrow, Charles J ^c,i   more..

^a Myanmar Oxford Clinical Research Unit   (Myanmar)

^b Department of Social Research Defence Services Medical Research Centre Tatkone Township   (Myanmar)

^c MAHIDOL UNIVERSITY   (Thailand)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e Institute of Medicine (1)   (Myanmar)

^f DEPARTMENT OF HEALTH   (Myanmar)

^g Ministry of Health ^*  (Myanmar)

^h WorldWide Antimalarial Resistance Network   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j Dev Care Foundation   (Bangladesh)

^k SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^l MONASH UNIVERSITY   (Australia)

^m Medical Action Myanmar   (Myanmar)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; K13 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; GENETIC MARKER; PROTOZOAL DNA;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CROSS-SECTIONAL STUDY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; MALARIA FALCIPARUM; MUTATION; MYANMAR; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; BANGLADESH; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; GENETIC MARKER; GENETICS; MALARIA, FALCIPARUM; PARASITOLOGY; PHYLOGEOGRAPHY; PREVALENCE; THAILAND;

ANTIMALARIALS; ARTEMISININS; BANGLADESH; CROSS-SECTIONAL STUDIES; DNA, PROTOZOAN; DRUG RESISTANCE; GENETIC MARKERS; GENOTYPE; MALARIA, FALCIPARUM; MUTATION; MYANMAR; PHYLOGEOGRAPHY; PLASMODIUM FALCIPARUM; PREVALENCE; SEQUENCE ANALYSIS, DNA; THAILAND;

EID: 84925354867     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70032-0     Document Type: Article

References (45)

1. Status report on artemisinin resistance: September 2014 2014, WHO, World Health Organization, Geneva.
2. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008, 359:2619-2620.
3. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
4. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014, 505:50-55.
5. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014, 371:411-423.
6. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012, 379:1960-1966.
7. Thriemer K, Hong NV, Rosanas-Urgell A, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother 2014, 58:7049-7055.
8. Saralamba S, Pan-Ngum W, Maude RJ, et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 2011, 108:397-402.
9. Witkowski B, Khim N, Chim P, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 2013, 57:914-923.
10. Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 2013, 57:818-826.
11. Rogers WO, Sem R, Tero T, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 2009, 8:10.
12. Denis MB, Tsuyuoka R, Poravuth Y, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2006, 11:1360-1366.
13. Saunders DL, Vanachayangkul P, Lon C, et al. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014, 371:484-485.
14. Carrara VI, Lwin KM, Phyo AP, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med 2013, 10:e1001398.
15. Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio JJ Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol 2014, 32:819-821.
16. Straimer J, Gnadig NF, Witkowski B, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 2015, 347:428-431.
17. Mok S, Ashley EA, Ferreira PE, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 2015, 347:431-435.
18. Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in southeast Asia. J Infect Dis 2014, published online Sept 1. 10.1093/infdis/jiu491.
19. Amaratunga C, Witkowski B, Dek D, et al. Plasmodium falciparum founder populations in western Cambodia have reduced artemisinin sensitivity in vitro. Antimicrob Agents Chemother 2014, 58:4935-4937.
20. Amaratunga C, Witkowski B, Khim N, Menard D, Fairhurst RM Artemisinin resistance in Plasmodium falciparum. Lancet Infect Dis 2014, 14:449-450.
21. Mohon AN, Alam MS, Bayih AG, et al. Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009-2013). Malar J 2014, 13:431.
22. Kamau E, Campino S, Amenga-Etego L, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis 2014, published online Nov 2. 10.1093/infdis/jiu608.
23. Conrad MD, Bigira V, Kapisi J, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One 2014, 9:e105690.
24. Torrentino-Madamet M, Fall B, Benoit N, et al. Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013. Malar J 2014, 13:472.
25. Taylor SM, Parobek CM, DeConti DK, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2014, published online Sept 1. 10.1093/infdis/jiu467.
26. Plucinski MM, Talundzic E, Morton L, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uige provinces, Angola. Antimicrob Agents Chemother 2015, 59:437-443.
27. Roper C, Alifrangis M, Ariey F, et al. Molecular surveillance for artemisinin resistance in Africa. Lancet Infect Dis 2014, 14:668-670.
28. Gething PW, Patil AP, Smith DL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011, 10:378.
29. Wellems TE, Hayton K, Fairhurst RM The impact of malaria parasitism: from corpuscles to communities. J Clin Invest 2009, 119:2496-2505.
30. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009, 4:e4551.
31. Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One 2013, 8:e57689.
32. Bustos MD, Wongsrichanalai C, Delacollette C, Burkholder B Monitoring antimalarial drug efficacy in the Greater Mekong subregion: an overview of in vivo results from 2008 to 2010. Southeast Asian J Trop Med Public Health 2013, 44(suppl 1):201-230.
33. Methods for surveillance of antimalarial drug efficacy 2009, WHO, World Health Organization, Geneva.
34. Flegg JA, Patil AP, Venkatesan M, et al. Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum. Malar J 2013, 12:249.
35. Matheron G Principles of geostatistics. Econ Geol 1963, 58:1246-1266.
36. Nyunt MH, Hlaing T, Oo HW, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the K13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis 2014, published online Dec 23. 10.1093/cid/ciu1160.
37. Kryazhimskiy S, Plotkin JB The population genetics of dN/dS. PLoS Genet 2008, 4:e1000304.
38. Starzengruber P, Swoboda P, Fuehrer HP, et al. Current status of artemisinin-resistant falciparum malaria in south Asia: a randomized controlled artesunate monotherapy trial in Bangladesh. PLoS One 2012, 7:e52236.
39. Mishra N, Kaitholia K, Srivastava B, et al. Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India. Malar J 2014, 13:284.
40. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 2015, published online Jan 15. 10.1038/ng.3189.
41. Miotto O, Almagro-Garcia J, Manske M, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 2013, 45:648-655.
42. White NJ Artemisinin resistance-the clock is ticking. Lancet 2010, 376:2051-2052.
43. Anderson TJ, Roper C The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop 2005, 94:269-280.
44. Hay SI, Okiro EA, Gething PW, et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010, 7:e1000290.
45. White NJ Antimalarial drug resistance. J Clin Invest 2004, 113:1084-1092.